41 programming-"the"-"DAAD"-"EURAXESS"-"Prof"-"U"-"IMPRS-ML" "UCL" Fellowship positions in United Kingdom
Sort by
Refine Your Search
-
evaluating patients for the MRI studies at UCL, as well as be trained to use the AI programme for assessing fat-fraction results from MRI scans. In addition, you will help coordinate with the six other UK
-
About us The UCL Institute for Global Health (IGH) is at the heart of UCL’s Grand Challenge of Global Health. The Institute’s vision is for a world where international policy on global health is
-
. UCL is ranked 9th in the 2024 QS World University Rankings, 2nd in the UK for research power (Research Excellence Framework 2021) and our Neuroscience degree is ranked first in Europe (U.S. News and
-
posts On-site nursery On-site gym Enhanced maternity, paternity and adoption pay Employee assistance programme: Staff Support Service Discounted medical insurance Visit https://www.ucl.ac.uk/work-at-ucl
-
organoid models of neurodevelopmental diseases to test advanced genetic therapies. It will be supervised by Professor Gabriele Lignani and is in collaboration with Dr Amy McTague at UCL Institute of Child
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
ensure high-quality research delivery. The postholder will be encouraged to pursue a higher degree (PhD/MD) as part of this programme. This is an exciting opportunity for a CRF to work at the frontiers
-
. UCL is ranked 9th in the 2024 QS World University Rankings, 2nd in the UK for research power (Research Excellence Framework 2021) and our Neuroscience degree is ranked first in Europe (U.S. News and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and